Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals reports revenue of $5.7M
June 2nd, 2006
Alnylam Pharmaceuticals, Inc., (ALNY) reported its consolidated financial results for the quarter ended March 31, 2006 and company highlights. "We have made considerable progress on multiple fronts since the beginning of the year, including a significant increase in revenue due to R&D funding from our pharmaceutical alliances, funding which we expect to form the basis for continued and sustainable revenues over the next several years," said John Maraganore, PhD, president and CEO of Alnylam. At March 31, 2006, Alnylam had cash, cash equivalents and marketable securities of $132.3 million, compared to $80.0 million at December 31, 2005. The increase...
Source: Medicine & Law Weekly (2006-06-02)
|
